Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,728.00
(
0.03%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
105.70
(
1.21%
)
Bitcoin
70,901.01
(
1.43%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 203263

Friday, 01/06/2017 2:34:06 PM

Friday, January 06, 2017 2:34:06 PM

Post# of 257262
FDA approves Lucentis for myopic choroidal neovascularization, a rare complication of severe near-sightedness:

http://finance.yahoo.com/news/fda-approves-genentech-lucentis-ranibizumab-230800100.html

The approval is based on a single phase-3 trial where the control arm was treatment with Visudyne! This is the first FDA approval for this indication.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now